Pay in 4 interest-free payments of $12.00 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
InChi: InChI=1S/C21H17NO3S2/c23-14-12-16(25-20(13-14)22-8-10-24-11-9-22)15-4-3-7-19-21(15)27-18-6-2-1-5-17(18)26-19/h1-7
PubMed PMID: 26185454
NI-57 was used at 10 µM final concentration in vitro and in cellular assays
Sephin1 was orally dosed to MPZmutant mice or SOD1mutant mice at 1 mg/Kg twice a day
Ledipasvir - CAS# 1256388-51-8 0153 InChi: InChI=1S/C21H17NO3S2/c23-14-12-16(25-20(13-14)22-8-10-24-11-9-22)15-4-3-7-19-21(15)27-18-6-2-1-5-17(18)26-19/h1-7Ledipasvir, also known as GS 5885, CAS No. 1256388 51 8, is an inhibitor of the hepatitis C virus NS5A protein and is a drug for the treatment of hepatitis C that was developed by Gilead Sciences. On October 10, 2014 the FDA approved the combination product ledipasvir 90 mg sofosbuvir 400 mg (trade name Harvoni). The ledipasvir sofosbuvir combination is a direct acting antiviral agent that interferes with HCV replication and can be used to treat